Radioembolization Therapy Market
Radioembolization Therapy Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031
Radioembolization Therapy Market Segmented By Transarterial Radioembolization, Selective Internal Radiation Therapy Procedure for Hepatocellular Carcinoma, Liver Cancer
Radioembolization Therapy Market Forecast and CAGR
According to the latest research by Persistence Market Research, Radioembolization Therapy market is set to witness a 6.7% growth during the year 2021-2031.
The market is expected to witness growth owing to increasing prevalence of liver cancer and hepatocellular cancer together with more focus of the key players on technological advancements. Also, increasing spending on the development of healthcare infrastructure particularly in the developing nations is contributing to the development of the market.
Find Out More about the Report Coverage
What is Driving Demand for Radioembolization Therapy?
The demand for the global market for radioembolization therapy is anticipated to grow on account of the increasing incidence of several types of hepatic cancer and the rising demand for minimally invasive procedure.
Moreover, the increasing expenditure to improve healthcare infrastructure and the growing research and development activities for technological advancements in the healthcare sector is expected to drive growth of radioembolization therapy market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Surge in Number of Cases of Liver Cancer, likely to drive Radioembolization Therapy Sales
The rising prevalence of various chronic diseases, such as cancer, are anticipated to boost the global radioembolization therapy market over the forecast period. As per the CDC (Centre for Disease Control and Prevention) report, in the US, 33,000 people are detected with liver cancer every year.
Among these, more than 27,000 people die from the disease and among which 10,000 women and 24,000 men get liver cancer, and around 9,000 women and 18,000 men die from the illness.
Moreover, the rate of people suffering from liver cancer has gradually been rising in the last decade. In addition, the rate of survival more than five years is tremendously low, with the percentage remaining between 4% -26%.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
US and Canada Radioembolization Therapy Market Outlook
The US and Canada radioembolization therapy market is anticipated to witness a healthy growth in the market due to growing number of ASCs (ambulatory surgery center) and increasing geriatric population in the US and Canada.
Also, developing preference for minimally invasive procedures have given rise to increased adoption of radioembolization procedures in these nations. As per the U.S. department of health and human services, Ambulatory surgery has shown to be popular amongst both patients and physicians and the amount of Medicare certified ambulatory surgery centers has risen steadily. These factors are contributing to the growth of market in US and Canada.
Explore Persistence Market Research’s expertise in promulgation of the business !
Europe Demand Outlook for Radioembolization Therapy
Europe is anticipated to be second leading region for market due to various factors. European market is set to witness gradual growth mainly because of the growing prevalence & incidence of cancer; availability of treatment and increasing awareness regarding overall health.
Moreover, initiatives such as funding and grants taken by government for the development of advanced techniques by means of interventional oncology will drive the market growth.
Who are the Key Manufacturers and Suppliers of Radioembolization Therapy?
Some of the leading manufacturers and suppliers of Radioembolization Therapy include
- Terumo Corporation
- Merit Medical Systems Inc.
- Cook Medical
- Boston Scientific Corporation
- Medtronic plc
- Stryker Corporation
- Depuy Synthes (J&J)
- BTG International Limited
The Radioembolization Therapy market is competitive. Also, key manufacturers are focusing on market expansion strategies in order to increase their foothold in the market. Additionally, major companies are spending extensively in the research and development activities to develop innovative products.
Worldwide, they are involved in long term collaborations with pharmaceutical companies, and are involved into alliances with other players in various countries to expand their business.
- Transarterial Radioembolization (TARE)
- Selective Internal Radiation Therapy (SIRT)
- Hepatocellular Carcinoma
- Liver Cancer
By End User
- Ambulatory Surgical Centers
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Radioembolization Therapy Market Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.